Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/29630
Type
ArticleCopyright
Restricted access
Embargo date
2028-08-30
Collections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record
PRENATAL TRANSMISSION OF SYPHILIS AND HUMAN IMMUNODEFICIENCY VIRUS IN BRAZIL: ACHIEVING REGIONAL TARGETS FOR ELIMINATION
Disease elimination
Human immunodeficiency virus
Infectious disease transmission
Mathematical models
Vertical transmission
Author
Affilliation
Columbia University. Divisions of General Medicine. New York, NY, USA.
Pan American Health Organization. Communicable Diseases and Health Analysis Department, HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections Unit. Washington DC, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Pan American Health Organization. Communicable Diseases and Health Analysis Department, HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections Unit. Washington DC, USA.
Massachusetts General Hospital. Department of Medicine. Divisions of General Medicine. Medical Practice Evaluation Center. Boston, MA, USA.
Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Division of General Medicine. Boston, MA, USA / Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Boston, MA, USA/ Harvard School of Public Health. Divisions of Infectious Diseases. Boston, MA, USA / Harvard School of Public Health. Department of Health Policy and Management. Boston, MA, USA.
Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Boston, MA, USA / Harvard School of Public Health. Divisions of Infectious Diseases. Boston, MA, USA.
Pan American Health Organization. Communicable Diseases and Health Analysis Department, HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections Unit. Washington DC, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Pan American Health Organization. Communicable Diseases and Health Analysis Department, HIV, Hepatitis, Tuberculosis and Sexually Transmitted Infections Unit. Washington DC, USA.
Massachusetts General Hospital. Department of Medicine. Divisions of General Medicine. Medical Practice Evaluation Center. Boston, MA, USA.
Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Division of General Medicine. Boston, MA, USA / Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Boston, MA, USA/ Harvard School of Public Health. Divisions of Infectious Diseases. Boston, MA, USA / Harvard School of Public Health. Department of Health Policy and Management. Boston, MA, USA.
Massachusetts General Hospital. Medical Practice Evaluation Center. Department of Medicine. Boston, MA, USA / Harvard School of Public Health. Divisions of Infectious Diseases. Boston, MA, USA.
Abstract
Background: The Pan-American Health Organization has called for reducing (1) human immunodeficiency virus (HIV) mother-to-child transmission (MTCT) to ≤0.30 infections/1000 live births (LB), (2) HIV MTCT risk to ≤2.0%, and (3) congenital syphilis (CS) incidence to ≤0.50/1000 LB in the Americas by 2015. Methods: Using published Brazilian data in a mathematical model, we simulated a cohort of pregnant women from antenatal care (ANC) through birth. We investigated 2 scenarios: "current access" (89.1% receive one ANC syphilis test and 41.1% receive 2; 81.7% receive one ANC HIV test and 18.9% receive birth testing; if diagnosed, 81.0% are treated for syphilis and 87.5% are treated for HIV) and "ideal access" (95% of women undergo 2 HIV and syphilis screenings; 95% receive appropriate treatment). We conducted univariate and multivariate sensitivity analyses on key inputs. Results: With current access, we projected 2.95 CS cases/1000 LB, 0.29 HIV infections/1000 LB, 7.1% HIV MTCT risk, and 11.11 intrauterine fetal demises (IUFD)/1000 pregnancies, with significant regional variation. With ideal access, we projected improved outcomes: 1.00 CS cases/1000 LB, 0.10 HIV infections/1000 LB, HIV MTCT risk of 2.4%, and 10.65 IUFD/1000 pregnancies. Increased testing drove the greatest improvements. Even with ideal access, only HIV infections/1000 LB met elimination goals. Achieving all targets required testing and treatment >95% and reductions in prevalence and incidence of HIV and syphilis. Conclusions: Increasing access to care and HIV and syphilis antenatal testing will substantially reduce HIV and syphilis MTCT in Brazil. In addition, regionally tailored interventions reducing syphilis incidence and prevalence and supporting HIV treatment adherence are necessary to completely meet elimination goals.
Keywords
Congenital syphilisDisease elimination
Human immunodeficiency virus
Infectious disease transmission
Mathematical models
Vertical transmission
Share